Name (Synonyms) | Correlation | |
---|---|---|
drug32 | 2: continuation of RAS blocker therapy Wiki | 1.00 |
drug21 | 1: discontinuation of RAS blocker therapy Wiki | 1.00 |
drug689 | Curently used therapy for COVID-19 non-critical patients Wiki | 1.00 |
drug1435 | Maraviroc+Favipiravir+CT Wiki | 1.00 |
drug928 | Favipiravir + Currently used therapy Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D002318 | Cardiovascular Diseases NIH | 0.21 |
D007239 | Infection NIH | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.21 |
There is one clinical trial.
Phase 2, randomized, open-label study to compare the safety and efficacy of maraviroc, favipiravir, and both drugs combined versus currently used therapy in hospitalized patients with pulmonary SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) infection (COVID-19)
Description: Percentage of patients free of mechanical ventilation or death
Measure: Patients free of mechanical ventilation or death Time: 28 days post startDescription: Percentage of patients free of mechanical ventilation or death
Measure: Patients free of mechanical ventilation or death Time: 5 days post startDescription: Time of improvement in at least 2 items of the 7-item World Health Organization (WHO) ordinal scale for COVID-19 in days.
Measure: Time of clinical improvement Time: 15 days post startDescription: Rate of change (Delta) in lymphocytes, monocytes and neutrophils with phosphorilated CCR5 as per measured by parameters of flow cytometry.
Measure: Rate of change in phosphorilated CCR5 Time: Day 10-1Description: Rate of change (Delta) in peripheral blood levels of proinflammatory cytokines and chemokynes [IL-6, IL-1b, TNF, IFNa, IFNg, VEGF, GM-CSF (granulocyte-macrophage colony stimulating factor), CCL2, CCL3, CCL4, CCL5, CXCL10 and CCL7], as per measured by parameters of flow cytometry
Measure: Rate of change in peripheral blood levels of proinflammatory cytokines and chemokynes Time: Day 10-1Description: Statistically significant change in the expression of activation [phosphorylated CCR5,CD38, CD126, CD127, CD25, CD86, CD83, CD40 (cluters of differentiation 38, 126, 127, 25, 86 and 40), HLA-DR (Human Leukocyte Antigen-DR isotype), Granzyme B, Perforin, CD107A, CD123, gp130, CD95], trafficking [CCR5, CCR2, CCR6, CCR7, CXCR1, CXCR3 , CXCR5, (CXC chemokine receptors 1, 3 and 5), CX3CR1 (CX3C chemokine receptor] and exhaustion (PD1, programmed death-1 receptor) markers in peripheral blood lymphocytes, neutrophils and monocytes, as per measured by parameters of flow cytometry.
Measure: Change in the trafficking and activation pattern of peripheral leukocytes Time: Day 10-1